The Short Answer
Solitary angiokeratomas are almost never Fabry disease. But if you have 3+ lesions, especially on lower abdomen or genitals, plus a family history of kidney disease or unexplained pain, Fabry risk rises sharply. Genetic testing (GLA panel) is warranted; Fabry affects 1 in 40,000 people and is treatable if caught early [3][4].
Red flags for Fabry disease include: (1) multiple angiokeratomas (especially clustered on lower abdomen, genitals, or buttocks), (2) family history of kidney disease, stroke, or heart problems before age 50, (3) unexplained burning pain in hands or feet (acroparesthesia), (4) heat intolerance or reduced sweating, (5) progressive hearing loss, or (6) corneal opacities (clouding) found on eye exam [3][4]. If you have 2+ of these, genetic testing is justified.
Fabry disease is X-linked recessive, meaning males are more severely affected than females. Males with Fabry typically show symptoms by age 20–30 (pain, angiokeratomas, kidney problems); females may have milder or delayed symptoms. Angiokeratomas appear in 70–80% of Fabry patients and are often the first visible sign [8]. A single lesion doesn't mean Fabry, but multiple lesions warrant a GLA gene panel.
Early enzyme replacement therapy (ERT) is transformative. Starting ERT within 1–2 years of diagnosis slows kidney function decline by 30–50% over 5 years and reduces stroke risk by 25–40% compared to untreated Fabry [8]. Delayed diagnosis means irreversible kidney damage; by age 40–50, many untreated Fabry patients need dialysis. Genetic testing costs $200–$400 and takes 2–3 weeks—a small investment for life-changing early intervention.
Try This Today
If you have multiple angiokeratomas or a family member with Fabry disease, ask your primary care doctor for a referral to a geneticist or metabolic specialist—not just a dermatologist. Bring a family tree showing any relatives with kidney disease, stroke, or heart problems. A single GLA gene panel can unlock decades of preventive therapy.